Publication & Citation Trends
Most Cited Works
Publications
43 total
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US PDF
Cited by 32
OpenAlex
Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd PDF
Cited by 43
OpenAlex
Real-World Treatment Patterns and Outcomes of Proteasome Inhibitor (PI: Bortezomib [V], Carfilzomib [K], or Ixazomib [I])-Lenalidomide/Dexamethasone (Rd)-Triplets By Prior Lenalidomide-Exposure in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Engaged in Routine Care in the United States OA
Cited by 0
Semantic Scholar
Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma PDF
Cited by 106
OpenAlex
A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agent PDF
Cited by 20
OpenAlex
Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia.
Cited by 8
Semantic Scholar
Cost differential of immuno-oncology therapy delivered at community versus hospital clinics.
Cited by 6
Semantic Scholar
PS1419 COMPARATIVE EFFECTIVENESS OF TRIPLETS CONTAINING BORTEZOMIB (B), CARFILZOMIB (C), DARATUMUMAB (D), OR IXAZOMIB (I) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN ROUTINE CARE IN THE US OA
Cited by 3
Semantic Scholar
Research Topics
Multiple Myeloma Research and Treatments
(18)
Protein Degradation and Inhibitors
(10)
Cancer Treatment and Pharmacology
(8)
Acute Myeloid Leukemia Research
(7)
Colorectal Cancer Treatments and Studies
(7)
Frequent Co-Authors
Affiliations
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
The Ohio State University Wexner Medical Center
AmerisourceBergen (United States)
Ascendis Pharma (Denmark)
Florida Cancer Specialists & Research Institute